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Itraconazoleandﬂuconazolehavebeenreportedtoinducehepatotoxicityinpatients.Thepresentstudywasdesignedtoinvestigate
the role of cytochrome P450 inhibitors, SKF 525A, and curcumin pretreatment on the cytotoxicity of antifungal drugs ﬂuconazole
and itraconazole. For 3 consecutive days, female rats were administered daily SKF 525A or curcumin (5 and 25mg/kg). Control
rats received an equivalent amount of dosed vehicle. The animals were anaesthetized 24 hours after receiving the last dose for liver
perfusion. Hepatocytes were then exposed to various concentrations of antifungal drugs. In vitro incubation of hepatocytes with
itraconazole revealed signiﬁcantly lower viability when compared to ﬂuconazole as assessed by lactate dehydrogenase, aspartate
aminotransferase and alanine aminotransferase activities. The cytotoxicity of itraconazole was enhanced when incubated with
hepatocytes pretreated with SKF 525A. SKF 525A had no eﬀects on the cytotoxicity of ﬂuconazole. Curcumin failed to either
increase or decrease the cytotoxicity of both antifungal drugs. ATP levels also showed signiﬁcant decrease in both itraconazole and
ﬂuconazoleincubatedhepatocytes.However,SKF525ApretreatedhepatocyteshadsigniﬁcantlylowerATPlevelsafteritraconazole
incubations. Collectively, these results conﬁrm the involvement of cytochrome P450 in the cytoprotection in itraconazole induced
hepatocyte toxicity. Diﬀerences of the eﬀects of SKF 525A on the cytotoxicity induced by itraconazole and ﬂuconazole may be due
to the diﬀerences on the metabolism of each antifungal drug in vivo.
Copyright © 2009 Nhareet Somchit et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Itraconazole and ﬂuconazole are triazole antifungal drugs,
which are multiringed synthetic compounds containing
three nitrogen atoms in the azole ring (Figure 1). The
triazole drugs are broad-spectrum antifungal agents and
are currently used to treat infections caused by various
pathogenic yeast and molds [1] .T h ed r u g sa r es h o w nt o
be eﬀective in both animal models [2, 3] and clinically
[4, 5]. Mechanistically, the drugs inhibit the synthesis
of ergosterol, which is an essential component of fungal
cell membranes causing abnormalities in the membrane
permeability, causing death to the cell [6].
The triazoles are thought to have greater antifungal
potency, lower toxicity, and a wider antifungal spectrum
than the older imidazole (Figure 1) antifungal drugs [1, 7].
However, there have been reports that itraconazole and
ﬂuconazole induced adverse drug reactions (ADRs). These
include mild reversible ADRs such as gastrointestinal dis-
turbances(dyspepsia, nausea, abdominal pain, and constipa-
tion), dizziness, and pruritis. Rare but severe hepatotoxicity
has also been reported in patients undergoing itraconazole
or ﬂuconazole therapy [8, 9]. The mechanism of triazole-
induced liver damage is unknown. Previous studies had
suggested that the hepatotoxicity could be due to metabolic
idiosyncrasy [9, 10].
Curcumin (difeuryloylmethane, Figure 1), the yellow
colourofturmeric(Curcumalonga),acommoningredientin
Asian cookery and traditional medicinal mixtures possesses
a wide range of pharmacological properties that include2 Journal of Toxicology
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Figure 1: Chemical structures. (a) Azole ring. (b) SFK 525A (Proadifen). (c) Curcumin
antiinﬂammatory, antioxidant, and anticancer eﬀects [11].
Curcumin is known to protect liver against the toxic
eﬀects of agents such as galactosamine, carbon tetrachloride,
and acetaminophen [12]. There is evidence that curcumin
enhanced liver detoxiﬁcation activity and removal of toxic
metabolites from the body [13]. Thapliyal and Maru [14]
reported curcumins inhibited the activity of cytochrome
P450 in vitro and in vivo.
Previously, we reported phenobarbital inhibited the in
vitro cytotoxicity of itraconazole but not ﬂuconazole in rat
hepatocytes [15]. It was concluded that cytochrome P450
maybeinvolvedinthemetabolismofitraconazoleintheliver
to remove the toxic metabolite/s and may not be involved
in the metabolism of ﬂuconazole. Recently, phenobarbital
has been shown to reduce the hepatotoxicity induced by
itraconazole in vivo [16, 17]. Inhibition of cytochrome P450
may increase the hepatotoxicity induced by itraconazole. In
vitrotechniqueshavebeenusedextensivelyforinvestigations
into hepatotoxicity of drugs and their metabolites [15,
18]. Therefore, the objective of this present study is to
evaluate the eﬀects of cytochrome P450 inhibitors, SKF
525A, and curcumin (Figure 1) on the in vitro cytotoxicity
of itraconazole and ﬂuconazole in rat hepatocytes.
2.MaterialsandMethods
2.1. Materials. The compounds were obtained from fol-
lowing sources: itraconazole was purchased from Janssen-
Cilag (US) and ﬂuconazole from Pﬁzer (France). Curcumin
was obtained from ChromaDex (US). Proadifen (SKF
525A), dimethyl sulfoxide (DMSO), tricaprylin, Phenobar-
bital sodium, Leibovitz Glutamax I medium (L-15), Hank’s
balanced salt solution (HBSS), collagenase A (0.5 units/mg),
hydrocortisone-21-sodium succinate, insulin, gentamycin,
trypanblue (0.4%solution), cellculturewater,bovine serum
albumin (fraction V) and foetal calf serum were purchased
from Sigma Chemical (UK). Sterile culture plates (60 and
90mm diameter) and 50-mL culture ﬂasks were purchased
from Nunclon1 (Nunc, UK). All other chemicals are of the
highest grade commercially available from Sigma Chemicals
or Aldrich Chemicals, UK.
2.2. Animals and Isolation of Hepatocytes. Female Sprague-
Dawley rats (200–250g in body weight, n = 6/group) were
housed in plastic cages with wood shavings as bedding.
The rats were fed on rat pellets and tap water ad libitum.
The care and experimental procedures were carried out in
strict compliance with the Animal Ethics Committee rules
and regulation followed in this institute. SKF 525A (5 and
25mg/kg in saline) and curcumin (5 and 25mg/kg in corn
oil) were injected intraperitoneally for 3 consecutive days.
Control animals received either saline or corn oil for 3
days. The animals were anaesthetized using pentobarbitone
sodium at 60mg/kg ip 24 hours after receiving the last dose
for liver perfusion.
Hepatocytes were isolated by a two-step collagenase
perfusion technique as previously described [15, 18, 19].
After isolation, hepatocyte suspensions were incubated at
a density of 1 × 106 viable cells/mL in L15 medium.
Itraconazole or ﬂuconazole (0.001, 0.01, 0.1, and 1.0mM)
were added in DMSO (ﬁnal DMSO concentration of 1.0%
v/v). Control hepatocyte suspensions were incubated with
an equivalent amount of DMSO. The ﬂasks were sealed in
95% O2/5% CO2 andplacedinashakingwaterbathat37◦C.
Samples were taken from these ﬂasks at time points of 0, 0.5,
1, 2, 3, 4, 5, and 6 hours.
2.3. Evaluation of Azole-Induced Cytotoxicity. Cytotoxicity
was quantitatively assessed by measurement of lactate dehy-
drogenase (LDH, EC 1.1.1.27) release from hepatocytes into
medium spectrophotometrically as described by Marshall
and Caldwell [20]. For each time point, cytotoxicity was
expressed as LDH activity in the medium as a percentage
of total LDH activity in that ﬂask (activity of LDH in the
medium plus activity released by viable cells lysed by Triton
X-100).
Enzyme activities of aspartate aminotransferase (AST,
EC 2.6.1.1) and alanine aminotransferase (ALT, EC 2.6.1.2)
were assayed after 6 hours incubations. AST and ALT
activities were assayed using commercial test kits from Sigma
Chemicals.
2.4. ATP Measurement. Separate incubations were per-
formed for ATP determination using a commercial ATP
assay system kit (Promega). Detailed methods as previously
described by Qian et al. [21].
2.5. Statistical Analysis. Data was expressed as mean + SD
and analysed using student’s t test or Analysis of Variance
(ANOVA). When interactions were signiﬁcant, Duncan
multiple posttest was performed. Values of P ≤ .05 was
considered signiﬁcant.Journal of Toxicology 3
3. Results
Figures 2(a) and 2(b) illustrate the eﬀects of cytochrome
P450 inhibitors, SKF 525A, and curcumin to the viability
of hepatocytes. Signiﬁcant reduction in cell viability was
observed in hepatocytes pretreated with 25mg/kg SKF 525A
only after 1 hour incubation. Curcumin at 25mg/kg body
weight reduced the viability of hepatocytes only after 6 hours
incubation. No signiﬁcant changes were detected in cell
viability for both SKF 525A and curcumin at 5mg/kg body
weight.
The cytotoxicity of ﬂuconazole and itraconazole was
observed to be time- and concentration-dependent (Figures
3(a) to 3(d)). Itraconazole induced statistically signiﬁcant
LDH leakage at 0.01mM (Figure 3(b)), whereas ﬂucona-
zole was cytotoxic at 1.0mM (Figure 3(c)). At the highest
drugconcentration,itraconazoleincubatedhepatocyteswere
approximately 58% viable compared to 77% for 1.0mM
ﬂuconazole (Figures 3(c) and 3(d)). At concentration of
0.001 and 0.01mM, both drugswere less toxic to hepatocytes
(Data not shown).
Curcumin pretreatment at 5 and 25mg/kg revealed no
eﬀects on the cytotoxicity of both ﬂuconazole and itracona-
zole. Interestingly, pretreatment of hepatocytes with 5 and
25mg/kg SKF 525A signiﬁcantly enhanced the cytotoxicity
of itraconazole, which can be clearly seen at 0.1 and 1.0mM
drug concentration (Figures 3(b) and 3(d)). The cytotoxicity
eﬀect was expressed in a dose dependent manner. The
pretreated hepatocytes were statistically less viable than the
non-pretreated cells immediately after 30 minutes incuba-
tion with 0.1mM itraconazole. Non-pretreated hepatocytes
and SKF 525A pretreated incubated with 0.1mM itracona-
zole for 6 hours had viability of approximately 45 and
74%, respectively (Figure 3(b)). The viable hepatocytes were
approximately only 9.5% after 6 hours incubation with
1.0mM itraconazole (Figure 3(d)). SKF 525A had no eﬀect
on the cytotoxicity of ﬂuconazole.
Similar trends were also observed in AST and ALT
activities. Pretreatment with SKF525A enhanced the release
of AST and ALT enzymes into the medium in itraconazole
incubated hepatocytes (Figures 4(b) and 4(d)). Fluconazole
only induced a marginal increase of both these enzymes
activities (Figures 4(a) and 4(c)). Exposure to the antifungal
drugs also caused concentration-related decrease in ATP was
observed. Itraconazole incubated hepatocytes showed lower
ATP levels when compared to ﬂuconazole (Table 1). It is
interesting to be observed after SKF 525A pretreatment, ATP
levels of hepatocytes incubated with itraconazole were even
lower (Table 1). SKF 525A had no eﬀects on the lowering of
ATP levels in ﬂuconazole incubated hepatocytes.
4. Discussion
The data presented in this current investigation reﬂect the
utilization of in vitro model and cytochrome P450 inhibitors
in evaluating the mechanism of cytotoxicity of antifungal
drugs ﬂuconazole and itraconazole. As our previous study
[15], itraconazole was more cytotoxic to hepatocytes than
ﬂuconazole. This present study revealed the cytotoxicity of
itraconazole was enhanced by a cytochrome P450 inhibitor
SKF 525A as judged by assessing LDH, AST, and ALT
activities. This inhibitor had no eﬀect on the cytotoxicity
of ﬂuconazole. From a mechanistic perspective, cytochrome
P450 plays a key role in the deactivation/detoxiﬁcation of
itraconazole or its metabolite/s. In addition, the hepatotox-
city of itraconazole also reduced hepatocytes ATP levels.
In vitro techniques are useful tools for investigating
toxicity of drugs and their metabolites [22]. The function
of cytochrome P450 in toxicity process was tested with P450
inhibitors (SKF 525A and curcumin). SKF 525A was slightly
toxic to hepatocytes at 25mg/kg pretreatment. Our previous
study revealed that phenobarbital (an inducer of cytochrome
P450) pretreatment prevented the cytotoxicity of itracona-
zole in vivo [17]. Based from our previous and current
ﬁndings, we can strongly conclude that cytochrome P450 is
involved in the detoxiﬁcation of itraconazole or its reactive
metabolite/s. Indeed, cytochrome P450 is responsible for the
metabolism of itraconazole and many other azole in the liver
[23]. However, we are still unsure of which metabolite/s or
the parent drug itself is responsible for the hepatotoxicity
observed clinically.
On the other hand, azole antifungal drugs have been
demonstrated to inhibit cytochrome P450 [24]. Itraconazole
has less inhibitive properties than the imidazoles in rat liver
microsomes [25]. At higher doses however, it is possible that
itraconazole can cause an autoinhibition of its metabolism
and induced enhanced toxicity as observed in this current
study. Even though ﬂuconazole has been shown to be a
potent cytochrome P450 inhibitor [26] ,t h i sd r u gi se x c r e t e d
mainly unchanged/not metabolized [26, 27]. Cytochrome
P450 may play a less role in the cytotoxicity of ﬂuconazole.
Inhibition of cytochrome P450 also may force an alternative
route for metabolism of itraconazole. With metabolism via
cytochromeP450inhibitedorimpaired(bySKF525Aand/or
auto-inhibition), this drug may then be metabolized by the
ﬂavin-containing monooxygenase (FMO). Rodriguez and
Acosta [9] postulated FMO metabolism maybe responsible
for ketoconazole-induced hepatotoxicity.
Curcumin had no eﬀects on the cytotoxicity of itracona-
zole even though it has been proven to be a cytochrome
P450 inhibitor in vivo and in vitro [14]. The failure
of curcumin to enhance itraconazole cytotoxicity may be
due to its inhibition of diﬀerent P450 isoenzymes or less
potency in comparison to SKF 525A [28]. Thapliyal and
Maru [14] demonstrated potent inhibition of cytochrome
P450 at 1% curcumin w/w in diet, the current doses
of curcumin used in this present study given IP may
not achieved the eﬀective dose. Furthermore, by giving
curcumin IP, this may change the metabolism of curcumin
that may reduce its potency. Curcumin however, plays an
important role in the hepatoprotectant in acetaminophen,
galactosamine, and carbon tetrachloride poisoning [12].
Glutathione has been implicated in the prevention of
hepatotoxicity of these compounds. Most likely, curcumin
is a better inducer of glutathione-related enzymes [13] than
inhibitor of cytochrome P450 [14]. Thus, glutathione may
not be an important detoxiﬁcation pathway of itracona-
zole.4 Journal of Toxicology
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Figure 2: Eﬀects of Cytochrome P450 inhibitors on the percentage viability of hepatocytes. ∗Signiﬁcant diﬀerent (P<. 05) when compared
to controls. Values are mean ± sd of 3 separate experiments.
Table 1: ATP levels in rats hepatocytes after ﬂuconazole or itraconazole incubations. Control and SKF 525A pretreated hepatocytes were
exposed to various concentrations of ﬂuconazole or itraconazole for 6 hours.
ATP (nmol/106 cells)
Drug Control hepatocytes 5mg/kg SKF 525A
pretreated hepatocytes
25mg/kg SKF 525A
pretreated hepatocytes
None (control) 27.1 ±3.5ax 25.2 ±2.7ax 23.2 ±2.9ax
Fluconazole (mM)
0.001 30.1 ±4.5ax 27.5 ±3.4ax 26.2 ±4.1ax
0.01 31.2 ±2.3ax 27.2 ±2.1ax 25.1 ±2.3ax
0.1 24.6 ±0.7bx 24.0 ±1.7ax 20.2 ±5.2ax
1.0 20.3 ±3.9bcx 20.1 ±2.4bx 18.5 ±6.7ax
Itraconazole (mM)
0.001 29.2 ±3.1ax 26.2 ± 3.1axy 21.2 ±3.9ay
0.01 22.7 ±2.4bx 19.3 ±2.8bcy 16.2 ±2.5by
0.1 16.3 ±3.5cdx 15.7 ±3.9cdx 12.3 ±2.0by
1.0 13.2 ±0.9dx 11.2 ±2.9dx 7.2 ±3.1cy
Values are mean ± sd of 3 separate experiments.
a–dMeans with diﬀerent superscript diﬀer signiﬁcantly (P<. 05) in the same column.
x-yMeans with diﬀerent superscript diﬀer signiﬁcantly (P<. 05) in the same row.
Results from this current study revealed ATP levels
in hepatocytes reduced dose-dependently after incubation
with both itraconazole and ﬂuconazole. Itraconazole being
more potent inhibitor and this was enhanced by pre-
treatment with SKF 525A. In contrast, triazole antifungal
drugs (itraconazole and ﬂuconazole) are shown to have
less eﬀect on the mitochondrial functions if compared to
imidazole antifungals (ketoconazole and miconazole) [9].
Imidazoles potently inhibit NADH oxidase and succinate
dehydrogenase. The drug concentration of 1.0mM used in
this study may be too high that caused disruption of the
whole hepatocytes rather than inhibition of mitochondrial
respiration.
The eﬀect of itraconazole and ﬂuconazole on the liver
h a sb e e nr e c o r d e di nv i v oi na na n i m a lm o d e l .S u b c h r o n i c
dosing of rats with itraconazole resulted in histologicalJournal of Toxicology 5
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Figure 3: Eﬀects of Cytochrome P450 inhibitors on the viability of hepatocytes treated with ﬂuconazole or itraconazole. Values are mean ±
sd of 3 separate experiments. ∗Signiﬁcant diﬀerent (P<. 05) when compared to controls and drug only groups. Drug = itraconazole or
ﬂuconazole; Cur = curcumin; SKF = SKF 525A.
changesinthelivermarkedbynecrosis,bileducthyperplasia,
and biliary cirrhosis [16]. These were accompanied by liver
enlargement and signiﬁcant increase in the liver enzyme
activities (alanine aminotransferase/ALT and alkaline phos-
phatase/ALP). However, rats dosed with ﬂuconazole only
revealed mild degenerative changes in the centrilobular
region of the livers with no changes in the liver enzyme
activities. Clinically, several patients on chronic itraconazole
therapy experienced elevated ALT and ALP activities [29].
Hepatotoxicity induced by itraconazole in patients although
rare, are more frequent when compared to ﬂuconazole
[1]. The mechanism underlying the hepatotoxicity remains6 Journal of Toxicology
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Figure 4: AST and ALT activities in rat hepatocytes exposed to various concentrations of itraconazole and ﬂuconazole. a–dMeans with
diﬀerent superscript diﬀer signiﬁcantly (P<. 05). Values are mean ± sd of 3 separate experiments.
unclear but cytochrome P450 may play a key role in
preventing certain azole induced liver toxicity especially
itraconazole. Based on the current ﬁndings and our previous
studies, it can be strongly suggested that the hepatotoxicity
could be due to metabolic idiosyncracy. In summary,
itraconazole is more cytotoxic than ﬂuconazole in vitro
and cytochrome P450 is involved in the detoxiﬁcation of
itraconazole but not ﬂuconazole.
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